Structural studies on radiopharmaceutical DOTA-minigastrin analogue (CP04) complexes and their interaction with CCK2

Piotr F J Lipiński1, Piotr Garnuszek2, Michał Maurin2

  • 1Neuropeptides Department, Mossakowski Medical Research Centre Polish Academy of Sciences, Pawińskiego 5 Str., 02-106, Warszawa, Poland. plipinski@imdik.pan.pl.

EJNMMI Research
|April 18, 2018
PubMed
Abstract

Insights

The minigastrin analogue CP04 shows similar binding affinity for the cholecystokinin receptor subtype 2 (CCK-2R) regardless of the radiometal used, supporting its use in theranostic applications for cancers like medullary thyroid carcinoma.

Area of Science:

  • Radiopharmaceutical chemistry
  • Molecular imaging
  • Cancer theranostics

Background:

  • The cholecystokinin receptor subtype 2 (CCK-2R) is overexpressed in certain cancers, notably medullary thyroid carcinoma (MTC), making it a key target for diagnostic imaging and targeted radionuclide therapy (TRNT).
  • Minigastrin analogue CP04 (DOTA-(DGlu)6-Ala-Tyr-Gly-Trp-Met-Asp-Phe-NH2) is a promising radiopharmaceutical candidate for MTC theranostics.

Purpose of the Study:

  • To evaluate the influence of different radiometals on the binding affinity of CP04 to CCK-2R.
  • To elucidate the binding mode of CP04 to CCK-2R through molecular modeling.

Main Methods:

  • In vitro binding affinity and cellular uptake studies using CP04 complexed with Gallium-68 ([68Ga]Ga3+) and Lutetium-177 ([177Lu]Lu3+).
  • Homology modeling and molecular docking to predict the binding structure of CP04 with CCK-2R.

Main Results:

  • CP04 exhibited comparable CCK-2R binding affinity and cellular uptake when complexed with either [68Ga]Ga3+ or [177Lu]Lu3+.
  • Molecular modeling revealed that the C-terminal of CP04 binds within the CCK-2R cavity, while the N-terminus with the radiometal remains exposed at the solvent-accessible outlet.
  • Radiometal complexation minimally affects the overall conformation of CP04, except in the immediate vicinity of the DOTA chelator.

Conclusions:

  • The binding affinity of CP04 to CCK-2R is relatively insensitive to the choice of radiometal, consistent with structure-activity relationship studies.
  • The proposed binding model supports the theranostic potential of CP04 for CCK-2R-expressing tumors.
  • The model aligns with existing structure-activity relationship data and partially explains site-directed mutagenesis findings.

Related Concept Videos

Drug-Receptor Interactions01:29

Drug-Receptor Interactions

Drug-receptor interaction describes the binding of receptors by drugs, but not all drug-receptor interactions result in activation and tissue response. For instance, the binding of agonists activates the receptor to generate a cellular reaction, while antagonists bind to receptors without causing their activation.
Several parameters, such as the drug's affinity for its receptor and its efficacy, which is its ability to activate the receptor, determine the drug's effect on the tissue....
7.6K
Assembly of Complex Microtubule Structures01:32

Assembly of Complex Microtubule Structures

Complex microtubule structures are present in resting cells and in dividing cells. In resting cells, they are responsible for maintaining the cellular architecture, tracks for intracellular transport, positioning of organelles, assembly of cilia and flagella. They mediate the bipolar spindle assembly for chromosomal segregation and positioning of the cell division plate in dividing cells. The formation of microtubule complex structures depends on the cell type, cell stage, and cell function.
2.5K
Drug-Receptor Interaction: Antagonist01:28

Drug-Receptor Interaction: Antagonist

An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
5.1K
Olfactory Receptors: Location and Structure01:03

Olfactory Receptors: Location and Structure

The process of olfaction, also known as the sense of smell, is a sophisticated chemical response system. The specialized sensory neurons that facilitate this process, known as olfactory receptor neurons, are situated in an upper segment of the nasal cavity, known as the olfactory epithelium. Olfactory sensory neurons are bipolar, with their dendrites extending from the epithelium's apex into the mucus that lines the nasal cavity. Airborne molecules, when inhaled, traverse the olfactory...
11.9K
Drug-Receptor Interaction: Agonist01:25

Drug-Receptor Interaction: Agonist

Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.2K
Internal Receptors01:31

Internal Receptors

Many cellular signals are hydrophilic and therefore cannot pass through the plasma membrane. However, small or hydrophobic signaling molecules can cross the hydrophobic core of the plasma membrane and bind to internal, or intracellular, receptors that reside within the cell. Many mammalian steroid hormones use this mechanism of cell signaling, as does nitric oxide (NO) gas.
74.7K